#China #Shanghai #financial results #Medical Imaging #United Imaging

United Imaging Healthcare Reports Impressive Q3 2025 Results

United Imaging Healthcare, a leader in advanced medical imaging and radiotherapy equipment, announced its financial performance for the first three quarters of 2025, showcasing remarkable growth and robust revenues. The company reported a striking rise in total revenue and net profit attributable to ordinary shareholders, reaching CNY 8.86 billion and CNY 1.05 billion, which reflects a year-on-year increase of 27.39% and 126.94%, respectively.

Q3 2025 Performance Highlights

In the third quarter alone, United Imaging achieved revenue of CNY 2.84 billion, marking a 75.41% year-on-year increase. The net profit attributable to ordinary shareholders after accounting for non-recurring profits was recorded at CNY 0.09 billion. The exceptional growth is attributed in part to the continued introduction of innovative high-end medical products that have gained widespread recognition in the market. Moreover, the expansion into international markets alongside an increase in service revenues has significantly bolstered the company’s financial standing.

Overseas Revenue Surge

During the first three quarters of 2025, United Imaging's overseas revenue surged to CNY 1.9 billion, representing a remarkable increase of 41.97% compared to the previous year. This figure accounts for 22.50% of the company's total revenue, highlighting the success of its overseas initiatives. The company's strategic focus on expanding its market reach and catering to international healthcare systems has proven fruitful, demonstrating its capability to leverage global market opportunities effectively.

Focus on Research and Development

Research and Development (R&D) continues to be a cornerstone of United Imaging’s strategy, significantly contributing to the proliferation of innovative products. In the first three quarters of 2025, the company’s R&D investments reached CNY 1.86 billion, a 13.48% rise year-on-year. This substantial investment has led to the launch of several groundbreaking products, including the uMR Ultra, uMI Panvivo, and uAngio AVIVA.

An important highlight includes the approval from China's National Medical Products Administration (NMPA) on September 29, 2025, for the uMR Ultra — a next-generation 3T MRI machine. With the necessary FDA clearance and the CE mark already obtained, the uMR Ultra is set to enter global markets, thereby enhancing United Imaging's product portfolio on an international scale.

Innovative Milestones

As of the report’s release, United Imaging has successfully introduced over 140 innovative products worldwide. Among them, 56 have received U.S. FDA clearance through the 510(k) process, while 64 products have been certified under the CE marking according to Medical Device Regulation (MDR) and Medical Device Directive (MDD). With operations spanning more than 90 countries and regions, the company is making significant strides toward establishing a worldwide presence.

Looking Ahead

United Imaging Healthcare is set to continue its journey of innovation-driven development, focusing on addressing global market demands and extending its international footprint. By enhancing healthcare systems across the globe, the company aims to contribute meaningfully to the sustainable progress of global health.

In conclusion, United Imaging Healthcare's impressive financial results for Q3 2025 underscore its ability to adapt and thrive in a competitive environment. With a solid strategy bolstered by innovation and international expansion, the company is undoubtedly well-positioned for continued growth and success in the medical imaging sector.